Despite the millions of deaths from tuberculosis each year and the threat of increased drug resistance, tuberculosis vaccine development has been hugely under-resourced. We set out here to evaluate the safety and immunogenicity of new subunit Constructs in Africa, a continent in desperate need of an effective tuberculosis vaccine. We shall employ two attenuated poxvirus vectors, modified virus Ankara and the FP9 adios strain that both have a marked capacity to boost pre-existing T cell responses, each expressing the secreted mycobacterium antigen, Ag85A. We shall initially test the vaccines individually at different doses and then in heterogonous prime-boost regimes to identify an immunisation regime that works well both in non-infected individuals and also in those already infected by M tuberculosis, a post-exposure vaccination group. In parallel we shall measure the incidence of tuberculosis infection and disease in various high-risk cohorts in this region to identify a group in whom tuberculosis subunit vaccines may in future be tested efficiently.
Funding SchemeCSC - Cost-sharing contracts
OX3 9DU Oxford/headington